Placebo to MK-8527

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIVHIV Pre-Exposure ProphylaxisHIV Pre-exposure ProphylaxisHuman Immunodeficiency Virus (HIV)

Phase 2

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

CompletedNCT06045507

Merck Sharp & Dohme LLCHIV, HIV Pre-exposure Prophylaxis

Start: 2023-11-08End: 2025-02-12Updated: 2026-01-07

Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Active, not recruitingNCT07044297

Merck Sharp & Dohme LLCHuman Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis

Start: 2025-07-31End: 2027-07-22Updated: 2026-09-18

Related Papers

Alimatravir Oral Once Monthly in Adults With Low Likelihood of HIV Exposure: A Randomized, Double-Blind, Placebo-Controlled Study.

PubMed2026-09-22